ACADIA Pharmaceuticals Announces Appointment of David C. Furlano, Ph.D., as Vice President, Regulatory Affairs
Monday January 9, 9:00 am ET
SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD - News), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system (CNS) disorders, today announced the appointment of David C. Furlano, Ph.D., as Vice President, Regulatory Affairs.
ADVERTISEMENT
"Dr. David Furlano brings to ACADIA more than 15 years of regulatory affairs experience. His broad experience of leading regulatory efforts for early and late-stage drug candidates, marketed products, and across therapeutic areas, including CNS indications, will be a great asset as our discovery and development pipeline continues to mature," said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA.
Dr. Furlano joins ACADIA from Vical, where he served as Executive Director, Regulatory Affairs and had managerial and strategic responsibility for all aspects of regulatory affairs. Prior to Vical, he was Executive Director, Regulatory Affairs and Compliance at Amylin Pharmaceuticals, where he led the U.S. regulatory affairs group. Dr. Furlano also has held regulatory positions at Ligand Pharmaceuticals, Abbott Laboratories and Parke-Davis Pharmaceuticals. Earlier in his career, he worked as a reviewer at the U.S. Food and Drug Administration and as a research scientist at the National Institutes of Health. Dr. Furlano received a Ph.D. degree in Medicinal Chemistry and Natural Products from the University of Iowa and a Bachelor of Science degree from the University of Connecticut.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for CNS disorders. ACADIA currently has four drug programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease, neuropathic pain, and glaucoma. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden. |
